Medulloblastoma (MB) is one of the most common forms of brain cancer in children. A subgroup of this, known as MYC-amplified medulloblastoma, is particularly associated with a high morbidity and mortality rate. This is mainly due to the high immunosuppressive and metastatic nature of the tumors.
A recent multicentric study has identified a promising combination therapy for treating such tumors in children. Using transcriptomic profiling and cell culture studies, researchers the University of Colorado and the German Cancer Consortium found that tacedinaline, an HDAC inhibitor, was particularly effective in downregulating MYC expression in MB tumors and inducing the activation of various immune factors such as pro-inflammatory cytokines and macrophages. When combined with an anti-CD47 monoclonal antibody, this treatment significantly improved the macrophage-mediated phagocytosis of MB…
